Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05807412 · ClinicalTrials.gov registry record · Early Phase 1

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

A Early Phase 1 study of Rhytides, sponsored by Lupo Center for Aesthetic and General Dermatology.

Completed
Registry status
Early Phase 1
Development phase
10
Enrollment target
1
Study location

NCT05807412 is a Early Phase 1 study of Rhytides that has completed, run by Lupo Center for Aesthetic and General Dermatology. The registered enrollment target is 10 participants, below the 21-participant average among 5 other Rhytides trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05807412, a Early Phase 1 study of Rhytides, has completed, sponsored by Lupo Center for Aesthetic and General Dermatology.

COMPLETED
Registry status
Early Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Ten subjects will be enrolled in the study. Each subject will have their left and right forehead randomly assigned to receive 4 units of PrabotulinumtoxinA-xvfs or OnabotulinumtoxinA. Subjects will be reassessed at 2 weeks for evaluation of rhytide diminution around each injection point to assess relative diffusion of each drug in the forehead.

Conditions Studied

Interventions

  • DRUG OnabotulinumtoxinA
  • DRUG PrabotulinumtoxinA-Xvfs

Study Locations (1)

Louisiana

  • Lupo Center for Aesthetic and General Dermatology - New Orleans

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2023-05-01
Est. Completion 2024-02-26
Phase Early Phase 1

What the Registry Record Tells You About NCT05807412

The ClinicalTrials.gov registry entry for NCT05807412 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 21-participant average among 5 other Rhytides trials with a reported enrollment target (52% lower). The listed sponsor is Lupo Center for Aesthetic and General Dermatology, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rhytides appearing as the primary indexed condition, and to 2 interventions - of which OnabotulinumtoxinA is the first listed.

NCT05807412 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT05807412 about?

NCT05807412 is a clinical study titled "Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides". Ten subjects will be enrolled in the study. Each subject will have their left and right forehead randomly assigned to receive 4 units of PrabotulinumtoxinA-xvfs or OnabotulinumtoxinA. Subjects will be reassessed at 2 weeks for evaluation of rhytide diminution around each injection point to assess re...

What is the current status of trial NCT05807412?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2023-05-01. Estimated completion is 2024-02-26.

What conditions does trial NCT05807412 study?

This clinical trial studies the following conditions: Rhytides.

What interventions are being tested in trial NCT05807412?

The interventions under investigation include: OnabotulinumtoxinA (DRUG), PrabotulinumtoxinA-Xvfs (DRUG).

Who is sponsoring clinical trial NCT05807412?

This trial is sponsored by Lupo Center for Aesthetic and General Dermatology, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05807412 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rhytides

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.